Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel P, Berry S, Nadler E, Bell C, et al. In a Survey, Marked Inconsistency in How Oncologists Judged Value of High-Cost Cancer Drugs in Relation to Gains in Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In a Survey, Marked Inconsistency in How Oncologists Judged Value of High-Cost Cancer Drugs in Relation to Gains in Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel P, Berry S, Nadler E, Bell C, et al
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Gains in healthy years of life and social value from cancer R&D
     
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • The standard treatment for prostate cancer used to require radical prostatectomy. Now, less invasive therapies like brachytherapy have been shown to have equal outcomes with fewer side effects.  
  • Increased use of medical technology, like colonoscopy and sigmoidoscopy for colon cancer screening, could save $178.2 billion between 2010 and 2035.